Project Grant R01HL177015
Award Date
5/1/25
Completion Date
1/31/29
Dollars Obligated
$393K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $344,304 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Trustees of Boston University, doing business as Boston University Medical Campus. The grant will fund a research project titled "A Learning Health System Approach to Improve the Effectiveness of Blood Transfusions During Septic Shock" over a period from August 15, 2024 to July 31, 2029. The project aims to investigate treatment...
This federal Project Grant award of $762,405.80 from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), aims to investigate the cellular and molecular mechanisms by which cell-free hemoglobin (CFH) and oxidized low-density lipoprotein (oxLDL) contribute to microvascular hyperpermeability and lung injury during sepsis. The research will focus on understanding how CFH-induced oxidation of LDL leads to the activation of the...
This Project Grant award of $1,149,840.00, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), supports research to identify the immunostimulatory ligands on stored red blood cells (RBCs) that trigger alloimmunization in transfusion recipients. The research aims to determine the specific Toll-like receptor (TLR) activation pathways in dendritic cells and B cells that lead to alloantibody production, with...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $637,526 to Duke University to conduct research on the effects of sickle cell disease (SCD) red blood cells (RBCs) on neutrophil activation and phenotypes. The research aims to systematically define the characteristics of sickle RBCs that cause neutrophil activation, and the resulting functional, phenotypic, and...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $598,228 to support research on the role of endoplasmic reticulum autophagy (ER-phagy) in regulating the immune response during sepsis. The research aims to define how macrophage ER-phagy mediates NLRP3 inflammasome activation and subsequent lung injury in sepsis, elucidate the underlying molecular mechanisms, and explore...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $827,753.90 in funding to Bloodworks (also known as Puget Sound Blood Center and Program) to investigate the role of thiol isomerases in promoting redox-sensitive vaso-occlusion in sickle cell disease. The award period is from August 1, 2024 to July 31, 2027. The research aims to mechanistically examine how thiol isomerases,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $615,455 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to the University of Tennessee Health Science Center in Memphis, TN. The grant supports research to investigate the role of eosinophils, a type of white blood cell, in promoting antibacterial immunity against Streptococcus pneumoniae (pneumococci) in the lungs. The project aims to determine the mechanisms and outcomes of interactions between...
This $739,362 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research to investigate non-immune factors that contribute to mortality during Streptococcus pneumoniae (pneumococcal) sepsis. The principal investigator will utilize a mouse model containing a novel genetic variant in the COQ6 gene to analyze how disruptions in mitochondrial function and metabolic remodeling impact inflammation and organ damage during...
The federal Project Grant award R00HL177831 was provided by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research Federal Grant Program (CFDA 93.837). The $465,000 grant supports research to investigate the mechanisms by which chronic inflammation disrupts the hemostatic balance in sickle cell disease (SCD). The key research aims are to determine how tumor necrosis factor-alpha (TNF-α) driven inflammation blocks autophagy and mitophagy in platelets...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,276,908 to Bloodworks (formerly Puget Sound Blood Center and Program) to conduct molecular and translational research on the mechanisms of disease in von Willebrand disease and sickle cell disease. The research aims to increase understanding of these blood disorders, identify new biomarkers, and explore potential new...